Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biktarvy Switch from Injectable CAB + RPV in HIV-1
NCT06104306Phase 4Completed
- Sponsor
- Gilead Sciences
- Start
- Dec 2023
- Primary completion
- Jan 2025
- Countries
- 3
01
Overview
A Phase 4 trial of bictegravir + emtricitabine + tenofovir alafenamide in human immunodeficiency virus type 1 infection (HIV-1), sponsored by Gilead Sciences. Started Dec 2023; status: completed.
02
Drugs
bictegravir + emtricitabine + tenofovir alafenamide
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT06104306.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06104306.